Allogene Therapeutics, Inc.

Contributing Author

Recent Articles by Allogene Therapeutics, Inc.

Apr-21	Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia ALLO GlobeNewswire
Apr-20	Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 ALLO GlobeNewswire
Apr-16	Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock ALLO +9.22% GlobeNewswire
Apr-15	Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases ALLO GlobeNewswire
Apr-14	Allogene Therapeutics Announces Pricing of Public Offering of Common Stock ALLO GlobeNewswire
Apr-13	Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock ALLO +12.50% GlobeNewswire
Apr-13	Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL ALLO +12.50% GlobeNewswire
Apr-10	Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 ALLO -6.53% GlobeNewswire
Mar-12	Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update ALLO -6.08% GlobeNewswire
Mar-02	Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update ALLO GlobeNewswire
Feb-05	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO -9.44% GlobeNewswire
Jan-08	Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T ALLO GlobeNewswire
Dec-15	Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis ALLO GlobeNewswire
Nov-10	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO GlobeNewswire
Nov-06	Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update ALLO +12.38% ALLO -5.41% GlobeNewswire
Nov-03	Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting ALLO GlobeNewswire
Oct-30	Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update ALLO GlobeNewswire
Aug-27	Allogene Therapeutics Announces Participation in Upcoming Investor Conference ALLO GlobeNewswire
Aug-13	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update ALLO GlobeNewswire
Aug-06	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update ALLO -5.36% GlobeNewswire
Aug-01	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma ALLO -12.20% GlobeNewswire
Jun-01	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO ALLO GlobeNewswire
May-23	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO GlobeNewswire
May-22	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel ALLO GlobeNewswire
May-13	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update ALLO -15.68% ALLO GlobeNewswire
May-06	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ALLO -20.99% GlobeNewswire

Allogene Therapeutics, Inc.

Recent Articles by Allogene Therapeutics, Inc.

Upgrade your Finviz experience